COVID-19 and COPD: a narrative review of the basic science and clinical outcomes.
Andrew HighamAlexander G MathioudakisJorgen VestboDave SinghPublished in: European respiratory review : an official journal of the European Respiratory Society (2020)
The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- chronic obstructive pulmonary disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- lung function
- type diabetes
- public health
- cystic fibrosis
- patient reported outcomes
- physical activity
- cardiovascular events
- drug induced
- stress induced